Alendronate Sodium

CHEMBL675 Phase 4 معتمد Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
325.1 g/mol
LogP
Phase
4

The sodium salt form of alendronic acid, a bisphosphonate medication that prevents bone breakdown by inhibiting osteoclast cells responsible for bone resorption. It is widely used to treat and prevent osteoporosis in postmenopausal women and men, and to treat Paget's disease of bone, significantly reducing the risk of fractures.

الوزن الجزيئي

325,1200 g/mol

TPSA

167,00 Ų

المجالات العلاجية

آلية العمل

Binds to hydroxyapatite crystals in bone, inhibiting osteoclast-mediated bone resorption by disrupting the mevalonate pathway within osteoclasts. This reduces bone turnover and increases bone mineral density.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

Binds to hydroxyapatite crystals in bone, inhibiting osteoclast-mediated bone resorption by disrupting the mevalonate pathway within osteoclasts. This reduces bone turnover and increases bone mineral density.

البنية ثنائية الأبعاد

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

NCCCC(O)(P(=O)([O-])O)P(=O)(O)O.[Na+]

InChI

InChI=1S/C4H13NO7P2.Na/c5-3-1-2-4(6,13(7,8)9)14(10,11)12;/h6H,1-3,5H2,(H2,7,8,9)(H2,10,11,12);/q;+1/p-1

Molecular Formula

C4H18NNaO10P2

HBD / HBA

8 / 11

الروابط القابلة للدوران

5

الذرات الثقيلة

18

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

The sodium salt form of alendronic acid, a bisphosphonate medication that prevents bone breakdown by inhibiting osteoclast cells responsible for bone resorption. It is widely used to treat and prevent osteoporosis in postmenopausal women and men, and to treat Paget's disease of bone, significantly reducing the risk of fractures.

Binds to hydroxyapatite crystals in bone, inhibiting osteoclast-mediated bone resorption by disrupting the mevalonate pathway within osteoclasts. This reduces bone turnover and increases bone mineral density.

Yes, Alendronate Sodium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL675. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 23681107. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.